You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEscitalopram
Accession NumberDB01175  (APRD00683)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Structure
Thumb
Synonyms
(+)-Citalopram
(S)-Citalopram
Escitalopram Oxalate
Escitalopramum
Esertia
S-(+)-Citalopram
S(+)-Citalopram
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-escitalopramtablet20 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-escitalopramtablet10 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Act Escitalopramtablet20 mgoralActavis Pharma Company2014-09-10Not applicableCanada
Act Escitalopramtablet10 mgoralActavis Pharma Company2014-09-10Not applicableCanada
Act Escitalopramtablet5 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Auro-escitalopramtablet10 mgoralAuro Pharma Inc2014-09-10Not applicableCanada
Auro-escitalopramtablet20 mgoralAuro Pharma Inc2014-09-10Not applicableCanada
Auro-escitalopramtablet15 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-escitalopramtablet5 mgoralAuro Pharma IncNot applicableNot applicableCanada
Cipralex -5mgtablet5 mgoralLundbeck Canada IncNot applicableNot applicableCanada
Cipralex -10mgtablet10 mgoralLundbeck Canada Inc2005-02-14Not applicableCanada
Cipralex -15mgtablet15 mgoralLundbeck Canada IncNot applicableNot applicableCanada
Cipralex -20mgtablet20 mgoralLundbeck Canada Inc2005-02-14Not applicableCanada
Cipralex Meltztablet (orally disintegrating)20 mgoralLundbeck Canada Inc2012-10-04Not applicableCanada
Cipralex Meltztablet (orally disintegrating)10 mgoralLundbeck Canada Inc2012-10-04Not applicableCanada
Escitalopramtablet20 mgoralSanis Health Inc2014-09-18Not applicableCanada
Escitalopramtablet10 mgoralSanis Health Inc2014-09-18Not applicableCanada
Escitalopramtablet20 mgoralPro Doc Limitee2014-09-15Not applicableCanada
Escitalopramtablet10 mgoralPro Doc Limitee2014-09-15Not applicableCanada
Escitalopramtablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Escitalopramtablet20 mgoralSivem Pharmaceuticals Ulc2015-01-14Not applicableCanada
Escitalopramtablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Escitalopramtablet10 mgoralSivem Pharmaceuticals Ulc2015-01-14Not applicableCanada
Escitalopram Oxalatetablet, film coated20 mg/1oralBlenheim Pharmacal, Inc.2016-02-11Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralMylan Institutional Inc.2012-02-29Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/1oralMylan Institutional Inc.2012-02-29Not applicableUs
Escitalopram Oxalatetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2012-02-29Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralBlenheim Pharmacal, Inc.2016-02-11Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralActavis Pharma, Inc.2015-04-01Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/1oralPhysicians Total Care, Inc.2012-10-16Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2012-10-16Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/1oralCardinal Health2002-08-14Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/1oralMylan Pharmaceuticals Inc.2012-02-29Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralCardinal Health2002-08-14Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2012-02-29Not applicableUs
Ipg-escitalopramtablet20 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-escitalopramtablet15 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-escitalopramtablet10 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-escitalopramtablet5 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-escitalopramtablet20 mgoralJamp Pharma Corporation2014-09-11Not applicableCanada
Jamp-escitalopramtablet10 mgoralJamp Pharma Corporation2014-09-11Not applicableCanada
Lexaprotablet, film coated10 mg/1oralbryant ranch prepack2002-08-14Not applicableUs
Lexaprotablet10 mg/1oralCardinal Health2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralSTAT Rx USA LLC2002-08-14Not applicableUs
Lexaprotablet, film coated20 mg/1oralbryant ranch prepack2002-08-14Not applicableUs
Lexaprotablet, film coated20 mg/1oralCardinal Health2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralUnit Dose Services2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralCardinal Health2002-08-14Not applicableUs
Lexaprotablet, film coated20 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-14Not applicableUs
Lexaprosolution5 mg/5mLoralForest Laboratories, Inc.2002-11-26Not applicableUs
Lexaprotablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-14Not applicableUs
Lexaprotablet, film coated20 mg/1oralForest Laboratories, Inc.2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralAidarex Pharmaceuticals LLC2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralForest Laboratories, Inc.2002-08-14Not applicableUs
Lexaprotablet5 mg/1oralPhysicians Total Care, Inc.2009-11-30Not applicableUs
Lexaprotablet, film coated20 mg/1oralAidarex Pharmaceuticals LLC2002-08-14Not applicableUs
Lexaprotablet, film coated5 mg/1oralForest Laboratories, Inc.2002-08-14Not applicableUs
Lexaprotablet20 mg/1oralPhysicians Total Care, Inc.2009-04-15Not applicableUs
Lexaprotablet, film coated20 mg/1oralREMEDYREPACK INC.2013-03-182016-03-11Us
Lexaprotablet20 mg/1oralCardinal Health2002-08-14Not applicableUs
Lexaprotablet10 mg/1oralPhysicians Total Care, Inc.2005-12-28Not applicableUs
Lexaprotablet, film coated5 mg/1oralSTAT Rx USA LLC2002-08-14Not applicableUs
Mar-escitalopramtablet15 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-escitalopramtablet5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-escitalopramtablet20 mgoralMarcan Pharmaceuticals Inc2014-09-10Not applicableCanada
Mar-escitalopramtablet10 mgoralMarcan Pharmaceuticals Inc2014-09-10Not applicableCanada
Mint-escitalopramtablet20 mgoralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-escitalopramtablet10 mgoralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-escitalopramtablet15 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-escitalopramtablet20 mgoralMylan Pharmaceuticals Ulc2014-09-10Not applicableCanada
Mylan-escitalopramtablet10 mgoralMylan Pharmaceuticals Ulc2014-09-10Not applicableCanada
Nat-escitalopramtablet10 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-escitalopramtablet20 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
PMS-escitalopramtablet15 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-escitalopramtablet5 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-escitalopramtablet20 mgoralPharmascience Inc2014-09-10Not applicableCanada
PMS-escitalopramtablet10 mgoralPharmascience Inc2014-09-10Not applicableCanada
Priva-escitalopramtablet20 mgoralPharmapar Inc2014-09-10Not applicableCanada
Priva-escitalopramtablet10 mgoralPharmapar Inc2014-09-10Not applicableCanada
Ran-escitalopramtablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.2014-09-10Not applicableCanada
Ran-escitalopramtablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.2014-09-10Not applicableCanada
Riva-escitalopramtablet5 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-escitalopramtablet15 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-escitalopramtablet20 mgoralLaboratoire Riva Inc2014-09-25Not applicableCanada
Riva-escitalopramtablet10 mgoralLaboratoire Riva Inc2014-09-25Not applicableCanada
Sandoz Escitalopramtablet20 mgoralSandoz Canada Incorporated2014-09-10Not applicableCanada
Sandoz Escitalopramtablet10 mgoralSandoz Canada Incorporated2014-09-10Not applicableCanada
Teva-escitalopramtablet10 mgoralTeva Canada Limited2014-09-10Not applicableCanada
Teva-escitalopramtablet15 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Teva-escitalopramtablet5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Teva-escitalopramtablet20 mgoralTeva Canada Limited2014-09-10Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-escitalopramtablet20 mgoralApotex Inc2014-09-10Not applicableCanada
Apo-escitalopramtablet10 mgoralApotex Inc2014-09-10Not applicableCanada
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2013-05-28Not applicableUs
Escitalopramtablet, film coated10 mg/1oralUnit Dose Services2012-03-14Not applicableUs
Escitalopramtablet, film coated5 mg/1oralHikma Pharmaceutical2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralRebel Distributors Corp2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralSTI Pharma LLC2013-09-12Not applicableUs
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2013-09-042016-04-05Us
Escitalopramtablet, film coated10 mg/1oralProficient Rx LP2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralSt. Mary's Medical Park Pharmacy2014-02-06Not applicableUs
Escitalopramtablet, film coated20 mg/1oralAmerican Health Packaging2013-07-01Not applicableUs
Escitalopramtablet, film coated10 mg/1oralHikma Pharmaceutical2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-05-02Not applicableUs
Escitalopramtablet20 mg/1oralCamber Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralSolco Healthcare US, LLC2012-03-15Not applicableUs
Escitalopramtablet, film coated20 mg/1oralProficient Rx LP2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2013-01-18Not applicableUs
Escitalopramtablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc2012-03-14Not applicableUs
Escitalopramtablet10 mg/1oralLupin Pharmaceuticals, Inc.2012-09-10Not applicableUs
Escitalopramtablet, film coated20 mg/1oralSolco Healthcare US, LLC2012-03-15Not applicableUs
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2013-02-13Not applicableUs
Escitalopramtablet, film coated10 mg/1oralSTI Pharma LLC2013-09-12Not applicableUs
Escitalopramtablet, coated20 mg/1oralDIRECT RX2015-01-01Not applicableUs
Escitalopramtablet, film coated20 mg/1oralApotex Corp.2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralAmerican Health Packaging2013-07-01Not applicableUs
Escitalopramtablet, film coated20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-05-08Not applicableUs
Escitalopramtablet10 mg/1oralCamber Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralSolco Healthcare US, LLC2012-03-15Not applicableUs
Escitalopramtablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralPreferred Pharmaceuticals, Inc.2014-09-25Not applicableUs
Escitalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2013-05-02Not applicableUs
Escitalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2013-02-18Not applicableUs
Escitalopramtablet, film coated20 mg/1oralCitron Pharma LLC2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralSTI Pharma LLC2013-09-12Not applicableUs
Escitalopramtablet, film coated10 mg/1oralApotex Corp.2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralBlue Point Laboratories2014-02-06Not applicableUs
Escitalopramtablet20 mg/1oralTYA Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet5 mg/1oralCamber Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralREMEDYREPACK INC.2016-01-14Not applicableUs
Escitalopramtablet, film coated5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2015-03-26Not applicableUs
Escitalopramsolution5 mg/5mLoralTaro Pharmaceuticals U.S.A., Inc.2012-05-03Not applicableUs
Escitalopramtablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralCitron Pharma LLC2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralApotex Corp.2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralBlue Point Laboratories2014-02-06Not applicableUs
Escitalopramtablet10 mg/1oralTYA Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralRebel Distributors Corp2012-03-14Not applicableUs
Escitalopramtablet, film coated5 mg/1oralAvera Mc Kennan Hospital2015-03-16Not applicableUs
Escitalopramtablet, film coated5 mg/1oralWest Ward Pharmaceuticals Corp2012-09-11Not applicableUs
Escitalopramtablet10 mg/1oralLegacy Pharmaceutical Packaging2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2015-03-09Not applicableUs
Escitalopramtablet, film coated20 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-09-14Not applicableUs
Escitalopramtablet, film coated5 mg/1oralBlue Point Laboratories2014-02-06Not applicableUs
Escitalopramtablet, film coated10 mg/1oralReady Meds2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralAccord Healthcare Inc.2013-01-15Not applicableUs
Escitalopramtablet, film coated10 mg/1oralWest Ward Pharmaceuticals Corp2012-09-11Not applicableUs
Escitalopramtablet20 mg/1oralLegacy Pharmaceutical Packaging2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralMc Kesson Contract Packaging2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralNorthwind Pharmaceuticals2014-03-21Not applicableUs
Escitalopramtablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralCitron Pharma LLC2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralInternational Labs, Inc.2013-09-19Not applicableUs
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2014-12-24Not applicableUs
Escitalopramtablet, film coated10 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-09-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralAurobindo Pharma Limited2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralbryant ranch prepack2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralAccord Healthcare Inc.2013-01-15Not applicableUs
Escitalopramtablet, film coated20 mg/1oralWest Ward Pharmaceuticals Corp2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralDispensing Solutions, Inc.2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2013-03-21Not applicableUs
Escitalopramtablet, film coated10 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-09Not applicableUs
Escitalopramtablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralInternational Labs, Inc.2013-09-20Not applicableUs
Escitalopramtablet, film coated5 mg/1oralAccord Healthcare Inc.2013-01-15Not applicableUs
Escitalopramtablet, film coated20 mg/1oralMajor Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralTeva Pharmaceuticals USA Inc2012-03-14Not applicableUs
Escitalopramtablet5 mg/1oralLupin Pharmaceuticals, Inc.2012-09-10Not applicableUs
Escitalopramtablet, film coated10 mg/1oralUnit Dose Services2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2012-03-14Not applicableUs
Escitalopramtablet20 mg/1oralREMEDYREPACK INC.2014-02-282016-04-05Us
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2014-11-28Not applicableUs
Escitalopramtablet, film coated5 mg/1oralJubilant Cadista Pharmaceuticals Inc.2014-11-07Not applicableUs
Escitalopramtablet, film coated10 mg/1oralAurobindo Pharma Limited2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralAidarex Pharmaceuticals LLC2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralbryant ranch prepack2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralUnit Dose Services2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralSTAT Rx USA LLC2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralCardinal Health2013-07-01Not applicableUs
Escitalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2013-09-052016-04-05Us
Escitalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2014-11-26Not applicableUs
Escitalopramtablet, film coated20 mg/1oralHikma Pharmaceutical2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralAurobindo Pharma Limited2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralbryant ranch prepack2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralMajor Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2012-03-14Not applicableUs
Escitalopramtablet20 mg/1oralLupin Pharmaceuticals, Inc.2012-09-10Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralAurobindo Pharma Limited2012-04-03Not applicableUs
Escitalopram Oxalatetablet5 mg/1oralTorrent Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatetablet10 mg/1oralTorrent Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralCitron Pharma LLC2012-04-03Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralAmneal Pharmaceuticals of New York, LLC2011-09-03Not applicableUs
Escitalopram Oxalatetablet20 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Escitalopram Oxalatetablet10 mg/1oralDIRECT RX2015-01-01Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/21oralMacleods Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatetablet10 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralSilarx Pharmaceuticals, Inc2013-06-12Not applicableUs
Escitalopram Oxalatetablet20 mg/1oralDIRECT RX2015-01-01Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/21oralMacleods Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatetablet5 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Escitalopram Oxalatetablet, film coated5 mg/1oralMacleods Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatetablet20 mg/1oralMajor Pharmaceuticals2014-10-15Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Escitalopram Oxalatetablet20 mg/1oralAidarex Pharmaceuticals LLC2012-09-11Not applicableUs
Escitalopram Oxalatetablet10 mg/1oralMajor Pharmaceuticals2014-10-15Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Escitalopram Oxalatetablet, film coated5 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Escitalopram Oxalatetablet10 mg/1oralCardinal Health2014-10-15Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralCamber Pharmaceuticals, Inc.2012-06-12Not applicableUs
Escitalopram Oxalatetablet20 mg/1oralTorrent Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralLeading Pharma, Llc2015-08-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CipralexNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4O4S742ANY
CAS number128196-01-0
WeightAverage: 324.3919
Monoisotopic: 324.163791509
Chemical FormulaC20H21FN2O
InChI KeyInChIKey=WSEQXVZVJXJVFP-FQEVSTJZSA-N
InChI
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
IUPAC Name
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
SMILES
CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • Benzonitrile
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Aryl halide
  • Aryl fluoride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Organoheterocyclic compound
  • Nitrile
  • Carbonitrile
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
  • 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile (CHEBI:36791 )
Pharmacology
IndicationLabeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients.
PharmacodynamicsEscitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase.
Mechanism of actionThe antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Escitalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
Related Articles
AbsorptionThe absolute bioavailability of citalopram is about 80% relative to an intravenous dose.
Volume of distribution
  • 12 L/kg
Protein binding~56%
Metabolism

Mainly hepatic. Escitalopram undergoes N-demethylation to S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT). CYP3A4 and CYP2C19 are the enzymes responsible for this N-demethylation reaction.

Route of eliminationFollowing oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance. Escitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT).
Half life27-32 hours
Clearance
  • oral cl=600 mL/min [Following oral administrations]
ToxicitySigns of overdose include convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Escitalopram Action PathwayDrug actionSMP00425
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Sodium-dependent serotonin transporter
Gene symbol: SLC6A4
UniProt: P31645
rs25531 Not AvailableA alleleIncrease risk of side effects (ie. headaches)19272758
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9729
Caco-2 permeable+0.6099
P-glycoprotein substrateSubstrate0.7597
P-glycoprotein inhibitor INon-inhibitor0.6361
P-glycoprotein inhibitor IIInhibitor0.9789
Renal organic cation transporterInhibitor0.6993
CYP450 2C9 substrateNon-substrate0.8401
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.5054
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5223
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.7452
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9054 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7735
hERG inhibition (predictor II)Inhibitor0.8994
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral5 mg
Tabletoral10 mg
Tabletoral15 mg
Tabletoral20 mg
Tablet (orally disintegrating)oral10 mg
Tablet (orally disintegrating)oral20 mg
Tablet, coatedoral20 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral5 mg/1
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Tablet, film coatedoral10 mg/21
Tablet, film coatedoral20 mg/21
Solutionoral5 mg/5mL
Prices
Unit descriptionCostUnit
Lexapro 20 mg tablet3.71USD tablet
Lexapro 10 mg tablet3.55USD tablet
Lexapro 5 mg tablet3.4USD tablet
Lexapro 5 mg/5ml Solution0.72USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1339452 No1997-09-092014-09-09Canada
CA2373757 No2010-01-052020-07-07Canada
US6916941 Yes2003-02-122023-02-12Us
US7420069 Yes2003-02-122023-02-12Us
USRE34712 No1994-09-142011-09-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00588 mg/mLALOGPS
logP3.58ALOGPS
logP3.76ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.26 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.02 m3·mol-1ChemAxon
Polarizability35.21 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Robert Dancer, “Escitalopram hydrobromide and a method for the preparation thereof.” U.S. Patent US20040167209, issued August 26, 2004.

US20040167209
General References
  1. Moore N, Verdoux H, Fantino B: Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol. 2005 May;20(3):131-7. [PubMed:15812262 ]
  2. Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M: A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin. 2006 Jul;22(7):1331-41. [PubMed:16834832 ]
  3. Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004 Sep;65(9):1190-6. [PubMed:15367045 ]
  4. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007 Feb;23(2):401-16. [PubMed:17288694 ]
  5. Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8. [PubMed:15695064 ]
External Links
ATC CodesN06AB10
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (1.09 MB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabEscitalopram may increase the anticoagulant activities of Abciximab.
AcenocoumarolEscitalopram may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Acetophenazine.
Acetylsalicylic acidEscitalopram may increase the antiplatelet activities of Acetylsalicylic acid.
AlteplaseEscitalopram may increase the anticoagulant activities of Alteplase.
AmisulprideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Escitalopram.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Escitalopram.
AnistreplaseEscitalopram may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Escitalopram is combined with Apixaban.
AprepitantThe serum concentration of Escitalopram can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Escitalopram is combined with Aripiprazole.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Escitalopram.
BenzquinamideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Benzquinamide.
BexaroteneThe serum concentration of Escitalopram can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Escitalopram can be decreased when it is combined with Boceprevir.
BortezomibThe metabolism of Escitalopram can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Escitalopram can be decreased when it is combined with Bosentan.
BuspironeBuspirone may increase the serotonergic activities of Escitalopram.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Escitalopram.
CarphenazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Carphenazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Chlorprothixene.
CimetidineThe serum concentration of Escitalopram can be increased when it is combined with Cimetidine.
CitalopramCitalopram may increase the QTc-prolonging activities of EsCitalopram.
Citric AcidEscitalopram may increase the anticoagulant activities of Citric Acid.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Escitalopram.
ClozapineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Clozapine.
CollagenaseThe risk or severity of adverse effects can be increased when Escitalopram is combined with Collagenase.
ConivaptanThe serum concentration of Escitalopram can be increased when it is combined with Conivaptan.
CyproheptadineThe therapeutic efficacy of Escitalopram can be decreased when used in combination with Cyproheptadine.
Dabigatran etexilateEscitalopram may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib.
DalteparinEscitalopram may increase the anticoagulant activities of Dalteparin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Escitalopram.
DeferasiroxThe serum concentration of Escitalopram can be decreased when it is combined with Deferasirox.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Escitalopram is combined with Deoxycholic Acid.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Escitalopram.
DesmopressinThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.
DextromethorphanEscitalopram may increase the serotonergic activities of Dextromethorphan.
DicoumarolEscitalopram may increase the anticoagulant activities of Dicoumarol.
DofetilideDofetilide may increase the QTc-prolonging activities of Escitalopram.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Escitalopram.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Escitalopram.
DroperidolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Droperidol.
Edetic AcidEscitalopram may increase the anticoagulant activities of Edetic Acid.
EnoxaparinEscitalopram may increase the anticoagulant activities of Enoxaparin.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Escitalopram.
Ethyl biscoumacetateEscitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.
FencamfamineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Fencamfamine.
FluconazoleThe metabolism of Escitalopram can be decreased when combined with Fluconazole.
FlupentixolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Fluspirilene.
FluvoxamineThe metabolism of Escitalopram can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumEscitalopram may increase the anticoagulant activities of Fondaparinux sodium.
FosaprepitantThe serum concentration of Escitalopram can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Escitalopram can be increased when it is combined with Fusidic Acid.
GlucosamineGlucosamine may increase the antiplatelet activities of Escitalopram.
GoserelinGoserelin may increase the QTc-prolonging activities of Escitalopram.
GranisetronGranisetron may increase the serotonergic activities of Escitalopram.
HaloperidolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Haloperidol.
HeparinEscitalopram may increase the anticoagulant activities of Heparin.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Escitalopram.
IcosapentEscitalopram may increase the antiplatelet activities of Icosapent.
IdelalisibThe serum concentration of Escitalopram can be increased when it is combined with Idelalisib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Escitalopram.
Insulin HumanEscitalopram may increase the hypoglycemic activities of Insulin Regular.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Escitalopram.
Ioflupane I 123Escitalopram may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IvabradineIvabradine may increase the QTc-prolonging activities of Escitalopram.
IvacaftorThe serum concentration of Escitalopram can be increased when it is combined with Ivacaftor.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Escitalopram.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Escitalopram.
LimaprostLimaprost may increase the antiplatelet activities of Escitalopram.
LinezolidLinezolid may increase the serotonergic activities of Escitalopram.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Escitalopram.
LithiumLithium may increase the serotonergic activities of Escitalopram.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Escitalopram.
LoxapineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Loxapine.
LuliconazoleThe serum concentration of Escitalopram can be increased when it is combined with Luliconazole.
MesoridazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Mesoridazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Methotrimeprazine.
Methylene blueEscitalopram may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Escitalopram.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Escitalopram.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Escitalopram.
MifepristoneMifepristone may increase the QTc-prolonging activities of Escitalopram.
MitotaneThe serum concentration of Escitalopram can be decreased when it is combined with Mitotane.
MolindoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Molindone.
MorphineMorphine may increase the serotonergic activities of Escitalopram.
NelfinavirThe metabolism of Escitalopram can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Escitalopram can be increased when it is combined with Netupitant.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Escitalopram.
ObinutuzumabThe risk or severity of adverse effects can be increased when Escitalopram is combined with Obinutuzumab.
OctreotideOctreotide may increase the QTc-prolonging activities of Escitalopram.
OlanzapineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Olanzapine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Escitalopram.
OmeprazoleThe serum concentration of Escitalopram can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ondansetron.
PalbociclibThe serum concentration of Escitalopram can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Paliperidone.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Escitalopram.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Escitalopram.
PerphenazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Perphenazine.
PhenelzinePhenelzine may increase the serotonergic activities of Escitalopram.
PhenindioneEscitalopram may increase the anticoagulant activities of Phenindione.
PhenprocoumonEscitalopram may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe metabolism of Escitalopram can be increased when combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Piperacetazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Promazine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Escitalopram.
QuetiapineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Quetiapine.
RemoxiprideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Reserpine.
ReteplaseEscitalopram may increase the anticoagulant activities of Reteplase.
RidogrelEscitalopram may increase the anticoagulant activities of Ridogrel.
RisperidoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Risperidone.
RivaroxabanEscitalopram may increase the anticoagulant activities of Rivaroxaban.
SertindoleThe risk or severity of adverse effects can be increased when Escitalopram is combined with Sertindole.
SiltuximabThe serum concentration of Escitalopram can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Escitalopram.
St. John's WortThe serum concentration of Escitalopram can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Escitalopram can be increased when it is combined with Stiripentol.
StreptokinaseEscitalopram may increase the anticoagulant activities of Streptokinase.
SulodexideEscitalopram may increase the anticoagulant activities of Sulodexide.
SulpirideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Sulpiride.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Escitalopram.
TelaprevirThe serum concentration of Escitalopram can be decreased when it is combined with Telaprevir.
TenecteplaseEscitalopram may increase the anticoagulant activities of Tenecteplase.
ThioridazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Thiothixene.
TipranavirTipranavir may increase the antiplatelet activities of Escitalopram.
TocilizumabThe serum concentration of Escitalopram can be decreased when it is combined with Tocilizumab.
TositumomabThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tositumomab.
TramadolEscitalopram may increase the neuroexcitatory activities of Tramadol.
TranylcypromineTranylcypromine may increase the serotonergic activities of Escitalopram.
TrazodoneEscitalopram may increase the serotonergic activities of Trazodone.
TreprostinilEscitalopram may increase the anticoagulant activities of Treprostinil.
TrichlormethiazideEscitalopram may increase the activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Escitalopram.
UrokinaseEscitalopram may increase the anticoagulant activities of Urokinase.
Vitamin EVitamin E may increase the antiplatelet activities of Escitalopram.
WarfarinEscitalopram may increase the anticoagulant activities of Warfarin.
ZiprasidoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ziprasidone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Owens MJ, Knight DL, Nemeroff CB: Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001 Sep 1;50(5):345-50. [PubMed:11543737 ]
  2. Owens JM, Knight DL, Nemeroff CB: [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine]. Encephale. 2002 Jul-Aug;28(4):350-5. [PubMed:12232544 ]
  3. Burke WJ: Escitalopram. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. [PubMed:12387707 ]
  4. Waugh J, Goa KL: Escitalopram : a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17(5):343-62. [PubMed:12665392 ]
  5. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O: Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003 Jun;167(4):353-62. Epub 2003 Apr 26. [PubMed:12719960 ]
  6. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
  7. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551 ]
  8. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C: An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett. 2009 Oct 25;462(3):207-12. doi: 10.1016/j.neulet.2009.07.030. Epub 2009 Jul 16. [PubMed:19616061 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
  2. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
  2. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 26, 2016 03:15